Woomera Therapeutics is developing monoclonal antibody therapies to treat Breast, Lung and other forms of cancer using our unique understanding of vasopressin oncology biology.

Our therapies are designed to target  specific mutations that are unique to tumor cells and critical to tumor survival.

Woomera Therapeutics was founded out of Dartmouth College in 2003. We are building on 30+ years of Founder Dr. William North's research into the role of vasopressin and the associated abnormal receptors in cancer.

Woomera has obtained granted patents on its core technology.